Drug Profile
Ucenprubart - Eli Lilly and Company
Alternative Names: CD200R Antibody; LY-3454738Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action CD200R1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Chronic urticaria
- Phase I Immunological disorders
Most Recent Events
- 12 Jan 2024 Eli Lilly and Company initiates a phase I pharmacokinetic trial (In volunteers) in USA (SC)(NCT06173895)
- 18 Dec 2023 Eli Lilly and Company plans a phase I pharmacokinetic trial (In volunteers) in USA (SC) in January 2024 (NCT06173895)
- 22 Jun 2023 Eli Lilly and Company plans a phase II trial for Atopic dermatitis (In adults, In the elderly) in Canada, China, Hungary, Italy, Japan, South Korea, Mexico, Poland, Taiwan, USA (SC) (NCT05911841)